Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.

Rivkin AZ, Ogilvie P, Dayan S, Yoelin SG, Weichman BM, Garcia JK.

Dermatol Surg. 2019 Feb 28. doi: 10.1097/DSS.0000000000001883. [Epub ahead of print]

PMID:
30829771
2.

Lip and Perioral Enhancement With Hyaluronic Acid Dermal Fillers in Individuals With Skin of Color.

Taylor SC, Downie JB, Shamban A, Few J, Weichman BM, Schumacher A, Gallagher CJ.

Dermatol Surg. 2019 Feb 13. doi: 10.1097/DSS.0000000000001842. [Epub ahead of print]

PMID:
30789512
3.

Safety and Effectiveness of the Hyaluronic Acid Dermal Filler VYC-17.5L for Nasolabial Folds: Results of a Randomized, Controlled Study.

Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, Lin V, Murphy DK.

Dermatol Surg. 2018 May;44(5):670-678. doi: 10.1097/DSS.0000000000001529.

4.

Safety and Effectiveness of VYC-15L, a Hyaluronic Acid Filler for Lip and Perioral Enhancement: One-Year Results From a Randomized, Controlled Study.

Geronemus RG, Bank DE, Hardas B, Shamban A, Weichman BM, Murphy DK.

Dermatol Surg. 2017 Mar;43(3):396-404. doi: 10.1097/DSS.0000000000001035.

PMID:
28157728
5.

Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.

Rivers JK, Bertucci V, McGillivray W, Muhn C, Rosen N, Solish N, Weichman BM, Wheeler S, Daniels SR, Gallagher CJ.

Dermatol Surg. 2015 Aug;41(8):950-9. doi: 10.1097/DSS.0000000000000424.

PMID:
26218728
6.

Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641.

Heaslip RJ, Lombardo LJ, Golankiewicz JM, Ilsemann BA, Evans DY, Sickels BD, Mudrick JK, Bagli J, Weichman BM.

J Pharmacol Exp Ther. 1994 Feb;268(2):888-96.

PMID:
8114002
7.

Rapamycin: a novel immunosuppressive macrolide.

Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM.

Med Res Rev. 1994 Jan;14(1):1-22. Review. No abstract available.

PMID:
8309312
8.

Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs.

Howell RE, Sickels BD, Woeppel SL, Jenkins LP, Rubin EB, Weichman BM.

J Pharmacol Exp Ther. 1994 Jan;268(1):353-8.

PMID:
8301576
9.

Rapamycin inhibits lymphocyte proliferation in a popliteal lymph node model via an IL-2-independent mechanism.

Warner LM, Lewis GM, Weichman BM, Sehgal SN.

Ann N Y Acad Sci. 1993 Jun 23;685:117-20. No abstract available.

PMID:
8363215
10.

WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.

Grimes D, Sturm RJ, Marinari LR, Carlson RP, Berkenkopf JW, Musser JH, Kreft AF, Weichman BM.

Eur J Pharmacol. 1993 May 19;236(2):217-28.

PMID:
8391458
11.

Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues.

Heaslip RJ, Grimes D, Berkenkopf JW, Ilsemann BA, Sickels BD, Weichman BM.

Eur J Pharmacol. 1993 Apr 6;234(2-3):247-54.

PMID:
8482329
13.

Comparison of the airway hyperreactivity produced by single and multiple antigen exposures in sensitized guinea pigs.

Howell RE, Sickels BD, Weichman BM.

Agents Actions. 1992 Nov;37(3-4):195-7.

PMID:
1295369
14.
15.

Characterization of phospholipase A2 activity in rat RPAR-induced pleurisy.

Marinari LR, Berkenkopf JW, Weichman BM.

Agents Actions. 1991 Sep;34(1-2):97-9.

PMID:
1838901
16.

Phospholipase A2 acyl-hydrolytic activity in rat RPAR-induced pleurisy.

Berkenkopf JW, Marinari LR, Weichman BM.

Agents Actions. 1991 Sep;34(1-2):93-6.

PMID:
1838900
17.

Evidence for a role of bradykinin in experimental pain models.

Chau TT, Lewin AC, Walter TL, Carlson RP, Weichman BM.

Agents Actions. 1991 Sep;34(1-2):235-8.

PMID:
1793037
18.

Comparison of several new 5-lipoxygenase inhibitors in a rat Arthus pleurisy model.

Berkenkopf JW, Weichman BM.

Eur J Pharmacol. 1991 Jan 25;193(1):29-34.

PMID:
1646730
19.

WY-50,295 tromethamine: a novel inhibitor of leukotriene-mediated reactions.

Weichman BM, Berkenkopf JW, Grimes D, Heaslip RJ, Sturm RJ, Chang JY.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:477-80. Review. No abstract available.

PMID:
1847784
20.

WY-50, 295 tromethamine: an orally active 5-lipoxygenase inhibitor with anti-allergic activity.

Weichman BM, Berkenkopf JW, Chang JY, Heaslip RJ, Kreft AF, Lewis AJ, Musser JH, Grimes D.

Agents Actions Suppl. 1991;34:201-9.

PMID:
1793064
21.

Pharmacologic modulation of D-49 phospholipase A2-induced paw edema in the mouse.

Calhoun W, Yu J, Sung A, Chau TT, Marshall LA, Weichman BM, Carlson RP.

Agents Actions. 1989 Jun;27(3-4):418-21.

PMID:
2801333
22.

Potential regulatory role of inflammatory cells on local vascular smooth muscle tone.

Sturm RJ, Holloway DA, Buckley S, Osborne MC, Grimes D, Weichman BM, Rimele TJ.

Agents Actions. 1989 Jun;27(3-4):414-7.

PMID:
2801332
23.

Effects of analgesics on bradykinin-induced writhing in mice presensitized with PGE2.

Walter T, Chau TT, Weichman BM.

Agents Actions. 1989 Jun;27(3-4):375-7.

PMID:
2801327
24.

Pemedolac: a novel and long-acting non-narcotic analgesic.

Chau TT, Weichman BM.

J Pharmacol Exp Ther. 1989 Mar;248(3):907-15.

PMID:
2703977
25.

Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac.

Hayward MA, Howard GA, Neuman RG, Wood DD, Weichman BM, Van Sickle DC.

Agents Actions. 1989 Mar;26(3-4):310-8.

PMID:
2525314
26.

Phospholipase A2-induced pleural inflammation in rats.

Weichman BM, Berkenkopf JW, Marshall LA.

Int J Tissue React. 1989;11(3):129-36.

PMID:
2533186
28.

Interaction of neutrophils with vascular smooth muscle: identification of a neutrophil-derived relaxing factor.

Rimele TJ, Sturm RJ, Adams LM, Henry DE, Heaslip RJ, Weichman BM, Grimes D.

J Pharmacol Exp Ther. 1988 Apr;245(1):102-11.

PMID:
3129547
29.

Temporal relationships of the anti-inflammatory effect of etodolac in the adjuvant arthritic rat.

Lee DK, Chau TT, Weichman BM, Wooley PH.

Proc Soc Exp Biol Med. 1988 Mar;187(3):273-7.

PMID:
2964641
30.

Leukotriene B4 production and pharmacologic regulation of reverse passive Arthus pleurisy: importance of antigen dose.

Weichman BM, Berkenkopf JW, Cullinan CA, Sturm RJ.

Agents Actions. 1987 Aug;21(3-4):351-4.

PMID:
2825482
31.

Inhibition of prostaglandin biosynthesis by etodolac. I. Selective activities in arthritis.

Neuman RG, Wilson BD, Barkley M, Kimball ES, Weichman BM, Wood DD.

Agents Actions. 1987 Jun;21(1-2):160-6.

PMID:
2957897
32.
34.

Synthesis and analgesic evaluation of 4-(2-heptyloxy)-7-[(Z)-(3-hydroxycyclohexyl)]indole: a caveat on indole-phenol bioisosterism.

Soll RM, Humber LG, Deininger D, Asselin AA, Chau TT, Weichman BM.

J Med Chem. 1986 Aug;29(8):1457-60.

PMID:
3735313
35.

Differential rank order of potency for antagonism of LTC4- and LTD4-induced contractions of guinea pig trachea.

Tucker SS, Weichman BM.

Prostaglandins Leukot Med. 1986 Jul;23(1):37-44.

PMID:
3016752
36.

Synthesis and LTD4 antagonist activity of 2-norleukotriene analogues.

Ku TW, McCarthy ME, Weichman BM, Gleason JG.

J Med Chem. 1985 Dec;28(12):1847-53.

PMID:
4068008
37.

Molecular heterogeneity of leukotriene receptors: correlation of smooth muscle contraction and radioligand binding in guinea-pig lung.

Mong S, Wu HL, Scott MO, Lewis MA, Clark MA, Weichman BM, Kinzig CM, Gleason JG, Crooke ST.

J Pharmacol Exp Ther. 1985 Aug;234(2):316-25.

PMID:
2991495
38.

Effect of calcium antagonists on the biosynthesis and contractile effects of peptidoleukotrienes in rhesus monkey lung.

Weichman BM, Muccitelli RM, Tucker SS, DeVan JF.

J Pharmacol Exp Ther. 1985 May;233(2):345-51.

PMID:
3999025
39.
40.

Synthesis and LTD4-antagonist activity of desamino-2-nor-leukotriene analogs.

Perchonock CD, Uzinskas I, Ku TW, McCarthy ME, Bondinell WE, Volpe BW, Gleason JG, Weichman BM, Muccitelli RM, DeVan JF, et al.

Prostaglandins. 1985 Jan;29(1):75-81.

PMID:
3975429
41.

Analysis of the antagonist profile of SK&F 88046 on guinea pig trachea.

Weichman BM, DeVan JF, Muccitelli RM, Tucker SS, Vickery LM, Wasserman MA.

Prostaglandins Leukot Med. 1984 Aug;15(2):167-75.

PMID:
6593742
42.

Leukotriene D4 elicits a non-sustained contraction of the guinea pig trachea in calcium-free buffer.

Weichman BM, Tucker SS.

Eur J Pharmacol. 1984 Jun 1;101(3-4):229-34.

PMID:
6432558
43.

Differential inhibition of LTD4-mediated bronchopulmonary effects by salbutamol.

Woodward DF, Weichman BM, Wasserman MA.

Eur J Pharmacol. 1984 Apr 20;100(2):219-22.

PMID:
6734717
44.
45.
46.

2-nor-leukotriene analogs: antagonists of the airway and vascular smooth muscle effects of leukotriene C4, D4 and E4.

Gleason JG, Ku TW, McCarthy ME, Weichman BM, Holden D, Osborn RR, Zabko-Potapovich B, Berkowitz B, Wasserman MA.

Biochem Biophys Res Commun. 1983 Dec 28;117(3):732-9.

PMID:
6320814
47.

Antagonism of the pulmonary effects of the peptidoleukotrienes by a leukotriene D4 analog.

Weichman BM, Wasserman MA, Holden DA, Osborn RR, Woodward DF, Ku TW, Gleason JG.

J Pharmacol Exp Ther. 1983 Dec;227(3):700-5.

PMID:
6655563
48.
49.

Effect of inhibition of thromboxane production on the leukotriene D4-mediated bronchoconstriction in the guinea pig.

Muccitelli RM, Osborn RR, Weichman BM.

Prostaglandins. 1983 Aug;26(2):197-206.

PMID:
6689082
50.

Effect of calcium antagonists on leukotriene D4-induced contractions of the guinea-pig trachea and lung parenchyma.

Weichman BM, Muccitelli RM, Tucker SS, Wasserman MA.

J Pharmacol Exp Ther. 1983 May;225(2):310-5.

PMID:
6842394

Supplemental Content

Loading ...
Support Center